News

Bevacizumab Halves Progression Risk in Recurrent Ovarian Cancer

Publish date: June 5, 2011

 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Dr. Aghajanian reported being a consultant to and receiving research funding from Genentech, manufacturer of bevacizumab, and the trial was sponsored by Genentech. Dr. Seidman reported being a consultant to Enzon and Wyeth; receiving honoraria from Abraxis BioScience, Genentech, and Genomic Health; and receiving research funding from Abraxis BioScience.

Pages

Recommended Reading

Fewer Than Half of Ovarian Cancer Patients Get Care Consistent with NCCN Guidelines
MDedge Hematology and Oncology
BRCA2 Gene Mutation Linked With Improved Survival in Ovarian Cancer
MDedge Hematology and Oncology
Gynecologic Cancer Symptoms May Be More Severe in Women With Psychiatric Histories
MDedge Hematology and Oncology
Antiviral Cidofovir May Enhance Therapies for HPV-Related Cancers
MDedge Hematology and Oncology
Symptom Experience in Patients with Gynecological Cancers: The Development of Symptom Clusters through Patient Narratives
MDedge Hematology and Oncology
PARP Inhibitor Olaparib Delays Progression in Ovarian Cancer
MDedge Hematology and Oncology
Three-Year Interval Safe for Cervical Cancer Screening after Negative HPV Test
MDedge Hematology and Oncology
Screening Does Not Reduce Ovarian Cancer Mortality
MDedge Hematology and Oncology
Screening Does Not Reduce Ovarian Cancer Mortality
MDedge Hematology and Oncology
Video Report: A Drug for Ovarian Cancer?
MDedge Hematology and Oncology